key: cord-1000554-gjpkam88
authors: Jaiswal, Vikash; Sarfraz, Zouina; Sarfraz, Azza; Mukherjee, Dattatreya; Batra, Nitya; Hitawala, Gazala; Yaqoob, Sadia; Patel, Abhinav; Agarwala, Preeti; Ruchika,; Sarfraz, Muzna; Bano, Shehar; Azeem, Nishwa; Naz, Sidra; Jaiswal, Akash; Sharma, Prachi; Chaudhary, Gaurav
title: COVID-19 Infection and Myocarditis: A State-of-the-Art Systematic Review
date: 2021-12-02
journal: J Prim Care Community Health
DOI: 10.1177/21501327211056800
sha: cf36f1b9922675fed2f07e5debabb83cd5e8e2a5
doc_id: 1000554
cord_uid: gjpkam88

BACKGROUND: COVID-19 was initially considered to be a respiratory illness, but current findings suggest that SARS-CoV-2 is increasingly expressed in cardiac myocytes as well. COVID-19 may lead to cardiovascular injuries, resulting in myocarditis, with inflammation of the heart muscle. OBJECTIVE: This systematic review collates current evidence about demographics, symptomatology, diagnostic, and clinical outcomes of COVID-19 infected patients with myocarditis. METHODS: In accordance with PRISMA 2020 guidelines, a systematic search was conducted using PubMed, Cochrane Central, Web of Science and Google Scholar until August, 2021. A combination of the following keywords was used: SARS-CoV-2, COVID-19, myocarditis. Cohorts and case reports that comprised of patients with confirmed myocarditis due to COVID-19 infection, aged >18 years were included. The findings were tabulated and subsequently synthesized. RESULTS: In total, 54 case reports and 5 cohorts were identified comprising 215 patients. Hypertension (51.7%), diabetes mellitus type 2 (46.4%), cardiac comorbidities (14.6%) were the 3 most reported comorbidities. Majority of the patients presented with cough (61.9%), fever (60.4%), shortness of breath (53.2%), and chest pain (43.9%). Inflammatory markers were raised in 97.8% patients, whereas cardiac markers were elevated in 94.8% of the included patients. On noting radiographic findings, cardiomegaly (32.5%) was the most common finding. Electrocardiography testing obtained ST segment elevation among 44.8% patients and T wave inversion in 7.3% of the sample. Cardiovascular magnetic resonance imaging yielded 83.3% patients with myocardial edema, with late gadolinium enhancement in 63.9% patients. In hospital management consisted of azithromycin (25.5%), methylprednisolone/steroids (8.5%), and other standard care treatments for COVID-19. The most common in-hospital complication included acute respiratory distress syndrome (66.4%) and cardiogenic shock (14%). On last follow up, 64.7% of the patients survived, whereas 31.8% patients did not survive, and 3.5% were in the critical care unit. CONCLUSION: It is essential to demarcate COVID-19 infection and myocarditis presentations due to the heightened risk of death among patients contracting both myocardial inflammation and ARDS. With a multitude of diagnostic and treatment options available for COVID-19 and myocarditis, patients that are under high risk of suspicion for COVID-19 induced myocarditis must be appropriately diagnosed and treated to curb co-infections.

Coronavirus disease 2019 (COVID-19) has led to fright among populations worldwide since it was first reported. 1 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was initially only considered to be a respiratory illness, but it is now recognized as a complex multi systems disease. 2, 3 Current literature suggests that the increased expression of angiotensin-converting enzyme 2 (ACE2) receptors of SARS-CoV-2 in cardiac myocytes accounts for the relatively high cardiovascular involvement in COVID- 19. 4 Comorbidities such as pre-existing cardiovascular diseases, hypertension and diabetes mellitus have led to worse prognosis among patients infected with COVID-19. 5 However, infected patients may experience added-on cardiovascular injuries, even in the absence of pre-existing cardiac disease. 6 Myocarditis is an inflammation of the heart muscle with symptoms such as chest pain, shortness of breath, and palpitations. 7 A study identified 42 COVID-19 patients with myocarditis, where fever was the most common presenting sign in 57% patients, and hypertension was the most pervasive comorbidity. 8 SARS-CoV-2 is posited to gain entry into human cells by binding the spike protein to the membrane protein angiotensin-converting enzyme 2 (ACE2). 9, 10 As depicted in Figure  1 , SARS-CoV-2 gains entry into the bloodstream, making its way to the heart and cardiac muscle. In the cardiomyocytes, the binding to ACE2 upregulates the receptor eventually leading to apoptosis, releasing viral and cardiac antigens. These antigens, when fixed to the antigen presenting cells (APCs), lead to the release of interleukins (IL1, IL6, IL12, TNF alpha), which when presented to CD4+ T helper cells, CD8+ T cells, and B cells, lead to autoreactive virus specific antibodies. The entire mechanism is posited to lead to myocarditis, with elevated inflammatory biomarkers, cardiac biomarkers, EKG changes, and symptoms such as shortness of breath and chest pain ( Figure 1 ).

While our systematic review does not delve into the myocardial effects of COVID-19 vaccines, a report in the New England Journal of Medicine identified 2 cases of histologically confirmed, fulminant myocarditis within 2 weeks of COVID-19 vaccination. 11 As of September 1 2021, the Centers for Disease Control and Prevention writes that the risk of myocarditis is far higher after COVID-19 infection as opposed to the mRNA virus. 12 Based on a study that identified 1.5 million inpatient records with COVID-19, myocarditis was uncommon among patients with or without COVID-19, however, there was a relatively higher risk in the 50 to 75 and over age groups. 12 The under 16 age group could be more prone due to the related multisystem inflammatory syndromes. 12 The paper also noted an 18-fold higher chance of developing myocarditis due to COVID-19. 12 The objective of this systematic review is to collate evidence about demographics, symptomatology, diagnostic techniques, and clinical outcomes of COVID-19 infected patients with myocarditis.

This systematic review was conducted and reported in conformity with the Cochrane and PRISMA (Preferred Reporting Items for Systematic review and Meta-Analyses) 2020 guidelines (Figure 2) . A comprehensive literature search was done using the search engines PubMed, Google Scholar, Cochrane CENTRAL, and Web of Science database from their inception up until August 31, 2021. The search terms included "SARS-CoV-2" and/or "COVID 19" and/or "myocarditis." Reference lists of included studies were also manually screened to identify any relevant studies that may have been missed during the search (umbrella review).

Articles retrieved from the systematic search were exported to EndNote Reference Library software (Clarivate), where duplicates were removed. 2 authors (V.J. and S.Y.) carried out an independent search and screened the titles and abstracts of the identified articles for inclusion. Afterward, full-text articles were reviewed to validate if they satisfied the inclusion criteria. Any discrepancies were resolved by discussion till consensus was achieved. Articles were included if they met all the prespecified eligibility criteria: (1) Patients with confirmed myocarditis in association with COVID-19; (2) Age groups > 18 years; (3) Cohorts, case series and case reports. Studies with post-mortem findings consistent with acute myocarditis were also included. All other studies were excluded.

Data extracted from articles included publication related characteristics (i.e. author/s, study design, number of patients, year of publication, and country) and patient related characteristics. In specific, demographics (age in years, gender, comorbidities), and clinical characteristics along with laboratory findings (particularly, inflammatory markers and cardiac enzymes) were documented (Tables 1-3) . Additionally, features of imaging modalities including Chest X-ray/CT scan, ECG, ECHO, CMR, and endomyocardial biopsy were noted. Management pertaining to both COVID-19 and myocarditis, complications, and final clinical outcomes were also recorded. All data was extracted onto a predesigned Excel spreadsheet.

In total, 54 case reports and 5 cohorts were identified comprising 215 adult patients. Among the 59 studies, the following comorbidities were noted among 178 patients. Hypertension (n = 92, 51.7%), diabetes mellitus type 2 (n = 47, 46.4%), cardiac comorbidities (n = 26, 14.6%), hyperlipidemia (n = 6, 3.4%), obesity (n = 5, 2.8%), ischemic stroke (n = 2, 1.1%), asthma (n = 2, 1.1%), hypothyroidism (n = 2, 1.1%), smoking (n = 2, 1.1%), cancer (n = 2, 1.1%), sarcoidosis (n = 1, 0.6%), epilepsy (n = 1, 0.6%), multiple sclerosis (n = 1, 0.6%), tuberculosis (n = 1, 0.6%), migraine (n = 1, 0.6%), spondylitis (n = 1, 0.6%), renal transplant (n = 1, 0.6%), and sleep apnea (n = 1, 0.6%) ( Table 1) .

Presenting symptoms on admission were acquired from 139 of 215 patients. They include cough (n = 86, 61.9%), fever (n = 84, 60.4%), shortness of breath (n = 74, 53.2%), chest pain (n = 61, 43.9%), diarrhea (n = 43, 30.9%), fatigue (n = 37, 26.6%), myalgia (n = 34, 24.5%), dyspnea (n = 17, 12.2%), hypoxia (n = 7, 5%), syncope (n = 6, 4.3%), tachycardia (n = 6 4.3%), hypotension (n = 4, 2.9%), tachypnea (n = 4, 2.9%), malaise (n = 4, 2.9%), vomiting (n = 4, 2.9%), ARDS (n = 1, 0.7%) ( Table 1) .

Of 215, inflammatory markers were reported among 185 patients. The inflammatory markers were elevated among 181 (97.8%) patients, and were normal in the remaining 4 (2.2%) patients. The cardiac markers were documented in 212 patients, of which 201 (94.8%) had elevated levels, whereas, 11 (5.2%) patients had normal cardiac markers. The mean value of CRP was 91.6 mg/L (Normal: Less than 10 mg/L. High: Equal to or greater than 10 mg/L). 71 The mean D-dimer value was 2419.2 ng/ml (reference concentration of D-dimer is < 500 ng/mL). 72 Mean ferritin laboratory values of 908.9 ng/ml (the normal range for ferritin in blood serum is: 20 to 250 ng/mL for adult males. 10 to 120 ng/mL for adult females) 72 ; and Interleukin 6 of 271.2 pg/mL (normal values: 5-15 pg/ml) were reported. 73 Troponin values were reported as 44.85 ng/ml (normal range for troponin I is between 0 and 0.04 ng/mL but for high-sensitivity cardiac troponin (hs-cTn) normal values are below14ng/L). 74 Radiographic imaging studies particularly, CT and Chest X-ray were indicated in COVID-19 patients (Table 2) . Radiographic findings were obtained from 120 individuals with COVID-19 myocarditis. Variable features were noticed, of which cardiomegaly (32.5%) was the most prominent. Precisely, 120 patient radiographic findings were noted, of which cardiomegaly (n = 39, 32.5%) was the most common occurrence. This was followed by pulmonary venous congestion (n = 27, 22.5%), ground glass opacity (n = 23, 19.2%), consolidation (n = 9, 7.5%), pericardial effusion (n = 3, 2.5%), pleural effusion (n = 1, 0.83%), and no abnormal finding (n = 5, 4.2%) were noted in the cohort of included patient (Table 2) . Electrocardiography (ECG) findings were obtained for 96 patients, which were normal in 2 (2%) patients while other patients had varied ECG findings comprising of ST segment elevation among 43 (44.8%) patients, T wave inversion in 7 (7.3%) patients, ST depression in 5 (5.2%) patients, sinus tachycardia in 11 (11.5%) patients, atrial fibrillation in 3 (3.1%) patients, sinus bradycardia in 1 (1%) patient, ventricular tachycardia in 2 (2%) patients, and finally LBBB was reported in 1 (1%) patient as well ( Table  2 ). Echocardiography was conducted in 175 patients, where 9 (51.4%) patients showed normal ejection fractions while 55 (31.4%) patients demonstrated reduced ejection fraction with a mean EF% of 35. Pericardial effusion was demonstrated in 12 (6.9%) patients, left ventricular hypertrophy in 7 (4%) patients, cardiomegaly in 7 (4%) patients, myocardial dyskinesia in 19 (10.9%) patients, and LV thrombus in 1 (0.6%) patient ( Table 2) .

Cardiovascular magnetic resonance (CMR) imaging is a non-invasive, gold standard test for diagnosing myocarditis. Our synthesis identifies that 42 of 215 patients underwent CMR and 36 of them were diagnosed with Myocarditis by the Lake Louis Criteria. The most common findings were increased signal intensity in T2 weighted imaging that is, myocardial edema (30/36; 83.3%) suggestive of myocardial inflammation and/or ischemia. Late Gadolinium enhancement was observed in 23/36 (63.9%) patients in both ischemic and non ischemic patterns. Hypokinesis and decreased systolic function were present in 8/36 (22.2%) and 6/36 (16.7%) patients respectively. Myocardial fibrosis was found in 1/36 (2.8%) patients. In total, 6 (14.3%) of 42 patients were found to have normal CMR findings (Table 2) .

On noting the biopsy and histopathological examination findings, and considering the invasive in nature, these findings were reported in 9 (4.2%) patients out of 215 ( Table 2) . The most common findings were multifocal or diffuse lymphocytic infiltrates in the myocardium and endothelium along with myocardial edema and necrosis. Other findings included positive myocardial anti-SARS COV nucleocapsid protein antibodies, cardiac hypertrophy, and multiple sites of ischemia and thrombosis with a left atrial and left pulmonary artery thrombus in one patient. 37 Only 1 (11.1%) patient had normal findings on biopsy.

The in-hospital management acquired from 165 patients comprised of azithromycin (n = 42, 25.5%), hydroxychloroquine (n = 41, 24.9%), methylprednisolone/steroid (n = 14, 8.5%), norepinephrine (n = 10, 6%), dobutamine (n = 7, 4.3%), tocilizumab (n = 6, 3.6%), and remdesivir (n = 1, 0.6%) ( Table 3 ). Standard care of treatment for COVID-19 was used for majority of the patients.

Complications during in-hospital stay reported in 128 patients included ARDS (n = 85, 66.4%), cardiogenic shock (n = 18, 14%), pleuritic chest pain (n = 6, 4.7%), multiorgan failure (n = 4, 3.1%), septic shock (n = 3, 2.3%), distributive shock (n = 2, 1.6%), sepsis (n = 2, 1.6%), bells palsy (n = 1, 0.8%) ( Table 3) . Of 85 patients, 55 (64.7%) survived, whereas 27 (31.8%) died. Three patients (3.5%) were in critical care unit on the last follow-up (Table 3 ).

This systematic review aimed to describe the symptomatology, prognosis, and clinical findings of patients with probable and confirmed COVID-19-related myocarditis. Frequent clinical findings of COVID-19 infection constitute fever, cough, shortness of breath, and fatigue. 75 The World Health Organization has cited fever and cough as striking features of COVID-19. 76 Fever, dyspnea, and/or chest pain are typical manifestations of myocarditis that tend to overlap with COVID-19 symptomatology, thus making the diagnosis challenging. 77, 78 Laboratory investigations such as rising levels of cardiac biomarkers and electrocardiogram findings may assist in diagnosing COVID-19 induced myocarditis.

Our systematic review finds hypertension was the most common comorbidity with prevalence among 51.7% patients. This was followed by diabetes mellitus type 2 (46.4%) and cardiac comorbidities (14.6%). Our synthesis also finds that the most common presenting symptoms on admission comprised of 61.9% patients with cough, 60.4% with fever, and 53.2% with shortness of breath. The inflammatory markers were elevated among 97.8% patients, and the cardiac markers were increased in 94.8% of patients. The mean CRP levels were 91.6 mg/L, mean D-dimer values were 2419.2 ng/ml, and mean ferritin was 908.9 ng/ml. Mean Interleukin 6 values were 271.2 pg/mL and troponin values were identified as 44.85 ng/ml. The most distinct radiographic findings were cardiomegaly noted in 32.5% patients, followed by pulmonary venous congestion (22.5%), and ground glass opacity (19.2%). On noting ECG findings, ST segment elevation was reported in 44.8% patients, sinus tachycardia in 11.5%, and T wave inversion in 7.3% patients. Echocardiography noted normal ejection fractions in 51.4% patients, but 31.4% had reduced ejection fraction with a mean percentage of 35%. CMR imaging identified increased signal intensity in T2 weighted imaging, with myocardial edema in 83.3% patients, suggesting myocardial ischemia/inflammation. Late gadolinium enhancement was observed in 63.9% patients. The biopsy and histopathological examination findings found multifocal or diffuse lymphocytic infiltrates in the myocardium and endothelium along with myocardial edema and necrosis. In-hospital management comprised of 22.5% patients treated with azithromycin, 24.9% with hydroxychloroquine, 8.5% with methylprednisolone/steroid and 6% with norepinephrine. Standard of care and treatment was used for the Figure 3 . Pirzada et al 79 elucidated the features of myocarditis found during the initial waves of the COVID-19 pandemic. The authors write that while the exact pathophysiology of severe COVID-19 was still elusive, a consistent observation of the pro-inflammatory surge, namely the cytokine storm was made. 79 Observations of elevated interleukins (IL-2R, IL-6, IL-10, TNF-α) were presented in a single-center cohort. 80 Viral myocarditis may be considered a direct response of autoimmunity, inflammation, or both. 81 Based on a cohort of 416 patients at the Renmin Hospital of Wuhan University conducted from January 20, 2020 until February 10, 2020, 82 (19.7%) patients had cardiac injury. 82 The cardiac involvement in the cohort of patients had a hazard ratio of 4.26, which is notably high. 82 Mortality in the myocardial injury group versus the general group was significantly higher (51.2% vs 4.5%, P < .001). 82 The symptoms of myocarditis among COVID-19 patients range from mild symptoms such as chest pain, fatigue, and palpitations to life-threatening symptoms such as sudden cardiac death associated with ventricular arrythmia or cardiogenic shock. Classically, myocarditis has a viral prodrome including myalgias, fever, and gastrointestinal/respiratory symptoms, with ranges of 10% to 80%. 79 Sawalha et al 83 identified COVID-19 related myocarditis focusing on management and outcomes until June 30, 2020, including a total of 14 cases. The authors found a male predominance (58%), with a median age of 50.4 years. 83 One thirds of all cases were younger than 40 years, and a majority of patients did not have comorbidities (50%), but among those that did have pre-existing conditions, hypertension was the most prevalent (33%). 83 Among the 14 patients, dyspnea/shortness of breath were the most common presenting features (75%), in addition to fever (75%). 83 On noting the hemodynamic status, 64% patients were in shock, of which 71% of the patients had cardiogenic shock, whereas 29% had a mixed septic and cardiogenic shock. 83 Around 42% of the patients had acute respiratory distress syndrome or developed it during the in-hospital period. 83 ECG findings were variable with ST-segment depression, ST-segment elevation, and T wave inversion occurring at 25% each. 83 Troponin was elevated in 91% of the cases, whereas pro-BNP and CK-MB were less frequently checked. 83 Among the 14 patients, echocardiography was performed in 83% of the case and 60% had a reduced ejection fraction. 83 Cardiac tamponade was reported in 20% of all echocardiograms, where diffuse hypokinesis was prevalent among 30% patients. 83 None of the patients had obstructive coronary disease. Around 50% patients required vasopressor support, with 25% of them warranting inotropic support. 83 Mechanical ventilation was utilized for 17% of the patients, of which ECMO was the most commonly used modality. 83 Many treatment modalities were used to manage myocarditis of which glucocorticoids (58%) were mostly used, followed by immunoglobulin therapy (25%) and colchicine (17%). Therapies to mitigate cytokine storm were interferon and tocilizumab (17% each). 83 Sawalha et al 83 found that 81% survived to discharge whereas 19% did not survive; the patients who did not survive were noted to have both myocarditis and ARDS.

Castiello et al 84 identified 38 case reports of COVID-19 patients with myocarditis based on the WHO/IFSC or ESC criteria. Around 45% of the cases had fever or a mild temperature increase; 21.1% had gastrointestinal symptoms, and 10.5% had a presenting or previous syncope. 84 Troponin levels varied substantially whereas BNP was raised in 57.9% patients. ECG findings were normal in 10.5% patients with variations among the rest. 84 Of 34 patients, only 18.4% patients had no functional or structural abnormality. 84 On noting CMR findings, myocardial inflammation and diffuse edema were captured in 50% patients. 84 EMB was performed only in 21.2% patients, where only 1 case reported the presence of SARS-CoV-2 in the cardiomyocytes. 84 Histological data obtained from autopsies were available for 10.5% patients, of which inflammatory infiltrates, accumulated inflammatory cells in the endothelium and signs of ferroptosis were noted. 84 The medical treatment was variable ranging from hydroxychloroquine (26.3%), tocilizumab (10.5%), lopinavir/ritonavir (7.9%), antibiotics (36.8%), steroids (34.2%), heart failure medications (36.8%), and anticoagulants (21.1%). Of 33 cases with reported outcomes, 84.8% patients survived, whereas 15.2% did not survive. 84 Rathore et al 8 present recent data, until January 5, 2021, of 42 patients with myocarditis and COVID-19, with 71.4% being males, and with a median age of 43.4 years. Hypertension was the most common finding in these patients, where cardiac biomarkers BNP and troponin were raised in 87% and 90% of the patients respectively. 8 ECG findings were nonspecific with T-wave and ST-segment changes noted. Echocardiogram commonly showed ventricular systolic dysfunction with cardiomegaly. 8 The commonest histopathological feature was diffuse lymphocytic inflammatory infiltrates. 8 Moreover, corticosteroids and antivirals were most frequently used. Around 40% of the patients required vasopressor support. 8 Of 41 patients, 67% survived, whereas 33% died. 8 Due to the sudden risk of worsening patient conditions and associations with myocarditis, knowledge of this cardiac complication due to COVID-19 is critical for healthcare workers across all settings. Kamarullah et al 85 also conducted a search until January 2021 where 18 patients were included. The findings were suggestive of the beneficial effects of corticosteroids in treating myocarditis associated with COVID-19; the most commonly applied steroids were hydrocortisone (5.5%), methylprednisolone (89%), and prednisolone (5.5%), with the intravenous route being the most common and duration of treatment ranging from 1 to 14 days. 85, 86 

This systematic review synthesizes the most recent evidence of COVID-19 infection and myocarditis, until August 31, 2021. Published literature obtained during the systematic search presents data collected until January 2021, enabling our collated findings, obtained until August 2021, to be a critical piece of information for healthcare workers worldwide. We present key findings about demographics, COVID-19 and myocarditis symptomatology, essential diagnostic techniques of use to clinicians, and clinical outcomes of interest of COVID-19 infection and myocarditis. The findings further strengthen the benefits of evidencebased healthcare where we gather evidence from reliable published literature to inform healthcare decisions, and reduce variations in healthcare delivery during the COVID-19 pandemic.

This systematic review has certain limitations. First, COVID-19 and myocarditis symptomatology may be overlapping, suggesting difficult clinical demarcations. Second, COVID-19 infections compounded with myocarditis were expected to be underreported as patients who did not previously have comorbidities presented with newly diminished ejection fractions and elevated myocardial markers. Thirdly, our systematic review presents that a low proportion of patents had confirmed myocarditis via MRI/endomyocardial biopsy. A plausible reason was the fear of contracting COVID-19 infection on undergoing MRI/endomyocardial biopsy. Fourthly, ECG and echocardiography were considered to be reliable screening tests, but not diagnostic tests, except for pericardial effusion. Lastly, while biomarkers such as troponin, BNP, and CK-MB were useful in diagnosing myocarditis, they are non-specific because the levels may also rise in other conditions such as demand ischemia and acute heart failure.

This systematic review presents findings about demographics, symptomatology, diagnostic techniques, and clinical outcomes of adult COVID-19 patients with myocarditis. A total of 229 patients were included in this analysis, who were diagnosed with myocarditis. The patients commonly presented with fever, cough, and shortness of breath making the clinical presentations difficult to differentiate. Elevated inflammatory and cardiac marker in addition to ECG and echocardiographic findings were useful indicators of myocardial disease. Gold standard testing such as MRI and endomyocardial biopsy were under-utilized suggesting that a definitive diagnostic approach may be required for those patients who fall under a high risk of suspicion for COVID-19 induced myocarditis. Due to the peaked risk of death among patients contracting both ARDS and myocardial inflammation, it is essential that healthcare workers are aware that myocarditis may be associated with COVID-19 infections. While the treatment approaches were variable across the cohort of patients included in this systematic review, further large-scale randomized controlled trials may help in establishing the best care of treatment for those with a definitive diagnosis of myocarditis with COVID-19.

Re: letter to the editor of Public Health in response to 'Non-COVID-19 visits to emergency departments during the pandemic: the impact of fear

The influence of Coronavirus disease-2019 (COVID-19) On Parkinson's disease: an updated systematic review

Cardio-Pulmonary sequelae in recovered COVID-19 patients: considerations for primary care

Coronavirus disease 2019 (COVID-19) and Cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome Coronavirus 2 infection

COVID-19 and multiorgan response

At the heart of COVID-19

Myocarditis and pericarditis following mRNA COVID-19 vaccination | CDC

Myocarditis associated with Covid-19 disease: a systematic review of published case reports and case series

Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management

SARS-CoV-2 post-infective myocarditis: the tip of COVID-19 immune complications? Ann Intensive Care

Myocarditis after covid-19 mRNA vaccination

Association between COVID-19 and myocarditis using hospital-based administrative data -United States

COVID-19 myopericarditis: it should be kept in mind in today's conditions

COVID-19 myocarditis: a case report

Proof of SARS-CoV-2 genomes in endomyocardial biopsy with latency after acute infection

First documentation of persistent SARS-Cov-2 infection presenting with late acute severe myocarditis

Coronavirus disease 2019 (Covid-19) presenting as purulent fulminant myopericarditis and cardiac tamponade: a case report and literature review

COVID-19) fulminant myopericarditis and acute respiratory distress syndrome (ARDS) in a middle-aged male patient

Acute perimyocarditis with cardiac tamponade in COVID-19 infection without respiratory disease

First case of COVID-19 complicated with fulminant myocarditis: a case report and insights

Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes

Viral heartbreak: a case of covid-19 myocarditis vs stressinduced cardiomyopathy

A recovered case of COVID-19 myocarditis and ARDS treated with corticosteroids, tocilizumab, and experimental AT-001. Case Rep

Diffuse myocardial inflammation in COVID-19 associated myocarditis detected by multiparametric cardiac magnetic resonance imaging

A recovered case of covid-19 myocarditis treated with IV immunoglobulin

COVID-19-associated myocarditis mimicking ST elevation myocardial infarction

Rhythm, conduction, and ST elevation with COVID-19: myocarditis or myocardial infarction? HeartRhythm Case Rep

Atypical presentation of COVID-19 as subclinical myocarditis with persistent high degree atrio-ventricular block treated with pacemaker implant

A case of novel coronavirus (COVID-19)-induced viral myocarditis mimicking a Takotsubo cardiomyopathy

The variety of cardiovascular presentations of COVID-19

Identification of COVID-19-associated myocarditis by speckle-tracking transesophageal echocardiography in critical care. Acta Colomb Cuidado Intensivo

Acute rehabilitation of a patient with COVID-19 myocarditis: a case report

Suspected myocarditis in patients with COVID-19: a multicenter case series

Acute myocarditis related to covid-19 infection: 2 cases report

Suspected subclinical myocarditis detected by cardiac magnetic resonance imaging late post COVID-19 recovery. J Cardiol Cases

Cardiac tamponade secondary to COVID-19. Case Rep

Fulminant myocarditis due to COVID-19

The enemy within: sudden-onset reversible cardiogenic shock with biopsy-proven cardiac myocyte infection by severe acute respiratory syndrome coronavirus 2

Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies

Cardioembolic stroke in a patient with coronavirus disease of 2019 (COVID-19) myocarditis: a case report

SARS-Cov-2 fulminant myocarditis: an autopsy and histopathological case study

Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19

Fatal lymphocytic cardiac damage in coronavirus disease 2019 (COVID-19): autopsy reveals a ferroptosis signature

Acute myopericarditis in a patient with mild SARS-CoV-2 respiratory infection

Delayed isolated peri-myocarditis in a covid-19 patient with respiratory symptoms but without lung involvement

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

COVID-19-associated myocarditis in an adolescent

Endothelial cell infection and endotheliitis in COVID-19

Terra incognita: clinically suspected myocarditis in a SARS-CoV-2 positive patient

Myocarditis detected after COVID-19 recovery

COVID-19 myocarditis and postinfection bell's palsy

Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin

COVID-19-Associated suspected myocarditis as the etiology for recurrent and protracted fever in an otherwise healthy adult

Acute myocarditis associated with COVID-19 infection

COVID-19-associated myocarditis presenting as new-onset heart failure and atrial fibrillation

Diabetes insipidus and concomitant myocarditis: a late sequelae of COVID-19 infection

COVID-19 "Fulminant Myocarditis" successfully treated with temporary mechanical circulatory support

Fulminant myocarditis as an early presentation of SARS-CoV-2

COVID-19-related myocarditis in a 21-year-old female patient

Systolic dysfunction and complete heart block as complications of fulminant myocarditis in a recovered COVID-19 patient

Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection

An 'asymptomatic' driver with COVID-19: atypical suspected myocarditis by SARS-CoV-2

Transient ST segment elevation in two patients with COVID-19 and a normal Transthoracic echocardiogram

COVID-19 (SARS-CoV-2) and the heart -an ominous association

Patients recovered from COVID-19 show ongoing subclinical myocarditis as revealed by Cardiac magnetic resonance imaging

Myocardial injury in severe COVID-19 is similar to pneumonias of other origin: results from a multicentre study

Cardiac injury is associated with inflammation in geriatric COVID-19 patients

Cardiovascular complications and its impact on outcomes in COVID-19

Mayo Clinic. C-reactive protein test -Mayo Clinic

Clinical: D-dimer, plasma

The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis

World Health Organization

Myocarditis in athletes Is a challenge: diagnosis, risk stratification, and uncertainties

COVID-19 and myocarditis: what do we know so far? CJC Open

Clinical and immunological features of severe and moderate coronavirus disease 2019

Autoimmunity in viral myocarditis

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Systematic review of COVID-19 related myocarditis: insights on management and outcome

COVID-19 and myocarditis: a systematic review and overview of current challenges

Corticosteroid therapy in management of myocarditis associated with COVID-19; a systematic review of current evidence

Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies

We would like to thank Janelle Tayo, Yoandra Diaz, Furqan Ahmad Jarullah for their early contributions to the manuscript.

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The author(s) received no financial support for the research, authorship, and/or publication of this article.